Global Anti-VEGF Ophthalmic Drug Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Anti-VEGF ophthalmic drugs are a class of drugs used for ophthalmic treatment. Their main function is to inhibit the activity of vascular endothelial growth factor.
The global Anti-VEGF Ophthalmic Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Ophthalmic Drug Industry Forecast” looks at past sales and reviews total world Anti-VEGF Ophthalmic Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Ophthalmic Drug sales for 2024 through 2030. With Anti-VEGF Ophthalmic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Ophthalmic Drug industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Ophthalmic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Ophthalmic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Ophthalmic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Ophthalmic Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Ophthalmic Drug.
United States market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Ophthalmic Drug players cover Eyetech, Pfizer Inc, Roche, Novartis, Regeneron, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Ophthalmic Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Anti-VEGF Ophthalmic Drug market?
What factors are driving Anti-VEGF Ophthalmic Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Ophthalmic Drug market opportunities vary by end market size?
How does Anti-VEGF Ophthalmic Drug break out by Type, by Application?
Anti-VEGF ophthalmic drugs are a class of drugs used for ophthalmic treatment. Their main function is to inhibit the activity of vascular endothelial growth factor.
The global Anti-VEGF Ophthalmic Drug market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Ophthalmic Drug Industry Forecast” looks at past sales and reviews total world Anti-VEGF Ophthalmic Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Ophthalmic Drug sales for 2024 through 2030. With Anti-VEGF Ophthalmic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Ophthalmic Drug industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Ophthalmic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Ophthalmic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Ophthalmic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Ophthalmic Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Ophthalmic Drug.
United States market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Ophthalmic Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Ophthalmic Drug players cover Eyetech, Pfizer Inc, Roche, Novartis, Regeneron, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Ophthalmic Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pegaptanib
- Ranibizumab
- Aflibercept
- Brolucizumab
- Faricimab
- Online Sales
- Hospital
- Clinic
- Retail Pharmacy
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Eyetech
- Pfizer Inc
- Roche
- Novartis
- Regeneron
- Bayer
- Regeneron Pharmaceuticals
- Genentech
- Samsung Bioepis
- Biogen
- Qilu Pharmaceutical
- Innovent Biologics
- Kanghong Pharmaceutical
- Taikang Biology
What is the 10-year outlook for the global Anti-VEGF Ophthalmic Drug market?
What factors are driving Anti-VEGF Ophthalmic Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Ophthalmic Drug market opportunities vary by end market size?
How does Anti-VEGF Ophthalmic Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Ophthalmic Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Ophthalmic Drug by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Ophthalmic Drug Segment by Type
2.2.1 Pegaptanib
2.2.2 Ranibizumab
2.2.3 Aflibercept
2.2.4 Brolucizumab
2.2.5 Faricimab
2.3 Anti-VEGF Ophthalmic Drug Sales by Type
2.3.1 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Ophthalmic Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Type (2019-2024)
2.4 Anti-VEGF Ophthalmic Drug Segment by Application
2.4.1 Online Sales
2.4.2 Hospital
2.4.3 Clinic
2.4.4 Retail Pharmacy
2.4.5 Others
2.5 Anti-VEGF Ophthalmic Drug Sales by Application
2.5.1 Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Ophthalmic Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Ophthalmic Drug Breakdown Data by Company
3.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Ophthalmic Drug Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Ophthalmic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Ophthalmic Drug Product Location Distribution
3.4.2 Players Anti-VEGF Ophthalmic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF OPHTHALMIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Ophthalmic Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Ophthalmic Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Ophthalmic Drug Sales Growth
4.4 APAC Anti-VEGF Ophthalmic Drug Sales Growth
4.5 Europe Anti-VEGF Ophthalmic Drug Sales Growth
4.6 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Ophthalmic Drug Sales by Country
5.1.1 Americas Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Ophthalmic Drug Sales by Region
6.1.1 APAC Anti-VEGF Ophthalmic Drug Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Ophthalmic Drug Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Ophthalmic Drug by Country
7.1.1 Europe Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Ophthalmic Drug by Country
8.1.1 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drug
10.3 Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drug
10.4 Industry Chain Structure of Anti-VEGF Ophthalmic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Ophthalmic Drug Distributors
11.3 Anti-VEGF Ophthalmic Drug Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF OPHTHALMIC DRUG BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Ophthalmic Drug Market Size Forecast by Region
12.1.1 Global Anti-VEGF Ophthalmic Drug Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Ophthalmic Drug Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Ophthalmic Drug Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Eyetech
13.1.1 Eyetech Company Information
13.1.2 Eyetech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.1.3 Eyetech Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Eyetech Main Business Overview
13.1.5 Eyetech Latest Developments
13.2 Pfizer Inc
13.2.1 Pfizer Inc Company Information
13.2.2 Pfizer Inc Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.2.3 Pfizer Inc Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Pfizer Inc Main Business Overview
13.2.5 Pfizer Inc Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.3.3 Roche Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Regeneron
13.5.1 Regeneron Company Information
13.5.2 Regeneron Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.5.3 Regeneron Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Main Business Overview
13.5.5 Regeneron Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.6.3 Bayer Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Regeneron Pharmaceuticals
13.7.1 Regeneron Pharmaceuticals Company Information
13.7.2 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.7.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Regeneron Pharmaceuticals Main Business Overview
13.7.5 Regeneron Pharmaceuticals Latest Developments
13.8 Genentech
13.8.1 Genentech Company Information
13.8.2 Genentech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.8.3 Genentech Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Genentech Main Business Overview
13.8.5 Genentech Latest Developments
13.9 Samsung Bioepis
13.9.1 Samsung Bioepis Company Information
13.9.2 Samsung Bioepis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.9.3 Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Samsung Bioepis Main Business Overview
13.9.5 Samsung Bioepis Latest Developments
13.10 Biogen
13.10.1 Biogen Company Information
13.10.2 Biogen Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.10.3 Biogen Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Biogen Main Business Overview
13.10.5 Biogen Latest Developments
13.11 Qilu Pharmaceutical
13.11.1 Qilu Pharmaceutical Company Information
13.11.2 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.11.3 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Qilu Pharmaceutical Main Business Overview
13.11.5 Qilu Pharmaceutical Latest Developments
13.12 Innovent Biologics
13.12.1 Innovent Biologics Company Information
13.12.2 Innovent Biologics Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.12.3 Innovent Biologics Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Innovent Biologics Main Business Overview
13.12.5 Innovent Biologics Latest Developments
13.13 Kanghong Pharmaceutical
13.13.1 Kanghong Pharmaceutical Company Information
13.13.2 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.13.3 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Kanghong Pharmaceutical Main Business Overview
13.13.5 Kanghong Pharmaceutical Latest Developments
13.14 Taikang Biology
13.14.1 Taikang Biology Company Information
13.14.2 Taikang Biology Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.14.3 Taikang Biology Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Taikang Biology Main Business Overview
13.14.5 Taikang Biology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Ophthalmic Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Ophthalmic Drug by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Ophthalmic Drug Segment by Type
2.2.1 Pegaptanib
2.2.2 Ranibizumab
2.2.3 Aflibercept
2.2.4 Brolucizumab
2.2.5 Faricimab
2.3 Anti-VEGF Ophthalmic Drug Sales by Type
2.3.1 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Ophthalmic Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Type (2019-2024)
2.4 Anti-VEGF Ophthalmic Drug Segment by Application
2.4.1 Online Sales
2.4.2 Hospital
2.4.3 Clinic
2.4.4 Retail Pharmacy
2.4.5 Others
2.5 Anti-VEGF Ophthalmic Drug Sales by Application
2.5.1 Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Ophthalmic Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Ophthalmic Drug Breakdown Data by Company
3.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Ophthalmic Drug Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Ophthalmic Drug Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Ophthalmic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Ophthalmic Drug Product Location Distribution
3.4.2 Players Anti-VEGF Ophthalmic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF OPHTHALMIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Ophthalmic Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Ophthalmic Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Ophthalmic Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Ophthalmic Drug Sales Growth
4.4 APAC Anti-VEGF Ophthalmic Drug Sales Growth
4.5 Europe Anti-VEGF Ophthalmic Drug Sales Growth
4.6 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Ophthalmic Drug Sales by Country
5.1.1 Americas Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Ophthalmic Drug Sales by Region
6.1.1 APAC Anti-VEGF Ophthalmic Drug Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Ophthalmic Drug Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Ophthalmic Drug by Country
7.1.1 Europe Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Ophthalmic Drug by Country
8.1.1 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drug
10.3 Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drug
10.4 Industry Chain Structure of Anti-VEGF Ophthalmic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Ophthalmic Drug Distributors
11.3 Anti-VEGF Ophthalmic Drug Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF OPHTHALMIC DRUG BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Ophthalmic Drug Market Size Forecast by Region
12.1.1 Global Anti-VEGF Ophthalmic Drug Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Ophthalmic Drug Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Ophthalmic Drug Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Eyetech
13.1.1 Eyetech Company Information
13.1.2 Eyetech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.1.3 Eyetech Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Eyetech Main Business Overview
13.1.5 Eyetech Latest Developments
13.2 Pfizer Inc
13.2.1 Pfizer Inc Company Information
13.2.2 Pfizer Inc Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.2.3 Pfizer Inc Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Pfizer Inc Main Business Overview
13.2.5 Pfizer Inc Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.3.3 Roche Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Regeneron
13.5.1 Regeneron Company Information
13.5.2 Regeneron Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.5.3 Regeneron Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Main Business Overview
13.5.5 Regeneron Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.6.3 Bayer Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Regeneron Pharmaceuticals
13.7.1 Regeneron Pharmaceuticals Company Information
13.7.2 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.7.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Regeneron Pharmaceuticals Main Business Overview
13.7.5 Regeneron Pharmaceuticals Latest Developments
13.8 Genentech
13.8.1 Genentech Company Information
13.8.2 Genentech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.8.3 Genentech Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Genentech Main Business Overview
13.8.5 Genentech Latest Developments
13.9 Samsung Bioepis
13.9.1 Samsung Bioepis Company Information
13.9.2 Samsung Bioepis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.9.3 Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Samsung Bioepis Main Business Overview
13.9.5 Samsung Bioepis Latest Developments
13.10 Biogen
13.10.1 Biogen Company Information
13.10.2 Biogen Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.10.3 Biogen Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Biogen Main Business Overview
13.10.5 Biogen Latest Developments
13.11 Qilu Pharmaceutical
13.11.1 Qilu Pharmaceutical Company Information
13.11.2 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.11.3 Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Qilu Pharmaceutical Main Business Overview
13.11.5 Qilu Pharmaceutical Latest Developments
13.12 Innovent Biologics
13.12.1 Innovent Biologics Company Information
13.12.2 Innovent Biologics Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.12.3 Innovent Biologics Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Innovent Biologics Main Business Overview
13.12.5 Innovent Biologics Latest Developments
13.13 Kanghong Pharmaceutical
13.13.1 Kanghong Pharmaceutical Company Information
13.13.2 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.13.3 Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Kanghong Pharmaceutical Main Business Overview
13.13.5 Kanghong Pharmaceutical Latest Developments
13.14 Taikang Biology
13.14.1 Taikang Biology Company Information
13.14.2 Taikang Biology Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
13.14.3 Taikang Biology Anti-VEGF Ophthalmic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Taikang Biology Main Business Overview
13.14.5 Taikang Biology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-VEGF Ophthalmic Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Ophthalmic Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Pegaptanib
Table 4. Major Players of Ranibizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players of Faricimab
Table 8. Global Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 9. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Table 10. Global Anti-VEGF Ophthalmic Drug Revenue by Type (2019-2024) & ($ million)
Table 11. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2019-2024)
Table 12. Global Anti-VEGF Ophthalmic Drug Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Anti-VEGF Ophthalmic Drug Sale by Application (2019-2024) & (K Units)
Table 14. Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2019-2024)
Table 15. Global Anti-VEGF Ophthalmic Drug Revenue by Application (2019-2024) & ($ million)
Table 16. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2019-2024)
Table 17. Global Anti-VEGF Ophthalmic Drug Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Anti-VEGF Ophthalmic Drug Sales by Company (2019-2024) & (K Units)
Table 19. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company (2019-2024)
Table 20. Global Anti-VEGF Ophthalmic Drug Revenue by Company (2019-2024) & ($ millions)
Table 21. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company (2019-2024)
Table 22. Global Anti-VEGF Ophthalmic Drug Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Anti-VEGF Ophthalmic Drug Producing Area Distribution and Sales Area
Table 24. Players Anti-VEGF Ophthalmic Drug Products Offered
Table 25. Anti-VEGF Ophthalmic Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Anti-VEGF Ophthalmic Drug Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global Anti-VEGF Ophthalmic Drug Sales Market Share Geographic Region (2019-2024)
Table 30. Global Anti-VEGF Ophthalmic Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Anti-VEGF Ophthalmic Drug Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2019-2024)
Table 34. Global Anti-VEGF Ophthalmic Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 37. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2019-2024)
Table 38. Americas Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024) & ($ millions)
Table 39. Americas Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 40. Americas Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 41. APAC Anti-VEGF Ophthalmic Drug Sales by Region (2019-2024) & (K Units)
Table 42. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Anti-VEGF Ophthalmic Drug Revenue by Region (2019-2024) & ($ millions)
Table 44. APAC Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 45. APAC Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 46. Europe Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 47. Europe Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024) & ($ millions)
Table 48. Europe Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 50. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 51. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Table 52. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 53. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Anti-VEGF Ophthalmic Drug
Table 55. Key Market Challenges & Risks of Anti-VEGF Ophthalmic Drug
Table 56. Key Industry Trends of Anti-VEGF Ophthalmic Drug
Table 57. Anti-VEGF Ophthalmic Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Anti-VEGF Ophthalmic Drug Distributors List
Table 60. Anti-VEGF Ophthalmic Drug Customer List
Table 61. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 62. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 63. Americas Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 64. Americas Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 65. APAC Anti-VEGF Ophthalmic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 66. APAC Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Europe Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Europe Anti-VEGF Ophthalmic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Type (2025-2030) & (K Units)
Table 72. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Type (2025-2030) & ($ millions)
Table 73. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Application (2025-2030) & (K Units)
Table 74. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Application (2025-2030) & ($ millions)
Table 75. Eyetech Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Eyetech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 77. Eyetech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Eyetech Main Business
Table 79. Eyetech Latest Developments
Table 80. Pfizer Inc Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Pfizer Inc Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 82. Pfizer Inc Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Pfizer Inc Main Business
Table 84. Pfizer Inc Latest Developments
Table 85. Roche Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Roche Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 87. Roche Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Roche Main Business
Table 89. Roche Latest Developments
Table 90. Novartis Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Novartis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 92. Novartis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Main Business
Table 94. Novartis Latest Developments
Table 95. Regeneron Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Regeneron Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 97. Regeneron Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Regeneron Main Business
Table 99. Regeneron Latest Developments
Table 100. Bayer Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Bayer Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 102. Bayer Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Bayer Main Business
Table 104. Bayer Latest Developments
Table 105. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 107. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Regeneron Pharmaceuticals Main Business
Table 109. Regeneron Pharmaceuticals Latest Developments
Table 110. Genentech Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Genentech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 112. Genentech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Genentech Main Business
Table 114. Genentech Latest Developments
Table 115. Samsung Bioepis Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Samsung Bioepis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 117. Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Samsung Bioepis Main Business
Table 119. Samsung Bioepis Latest Developments
Table 120. Biogen Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Biogen Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 122. Biogen Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Biogen Main Business
Table 124. Biogen Latest Developments
Table 125. Qilu Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 127. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Qilu Pharmaceutical Main Business
Table 129. Qilu Pharmaceutical Latest Developments
Table 130. Innovent Biologics Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Innovent Biologics Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 132. Innovent Biologics Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Innovent Biologics Main Business
Table 134. Innovent Biologics Latest Developments
Table 135. Kanghong Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 137. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Kanghong Pharmaceutical Main Business
Table 139. Kanghong Pharmaceutical Latest Developments
Table 140. Taikang Biology Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Taikang Biology Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 142. Taikang Biology Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Taikang Biology Main Business
Table 144. Taikang Biology Latest Developments
Table 1. Anti-VEGF Ophthalmic Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Ophthalmic Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Pegaptanib
Table 4. Major Players of Ranibizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players of Faricimab
Table 8. Global Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 9. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Table 10. Global Anti-VEGF Ophthalmic Drug Revenue by Type (2019-2024) & ($ million)
Table 11. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2019-2024)
Table 12. Global Anti-VEGF Ophthalmic Drug Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Anti-VEGF Ophthalmic Drug Sale by Application (2019-2024) & (K Units)
Table 14. Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2019-2024)
Table 15. Global Anti-VEGF Ophthalmic Drug Revenue by Application (2019-2024) & ($ million)
Table 16. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application (2019-2024)
Table 17. Global Anti-VEGF Ophthalmic Drug Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Anti-VEGF Ophthalmic Drug Sales by Company (2019-2024) & (K Units)
Table 19. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company (2019-2024)
Table 20. Global Anti-VEGF Ophthalmic Drug Revenue by Company (2019-2024) & ($ millions)
Table 21. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company (2019-2024)
Table 22. Global Anti-VEGF Ophthalmic Drug Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Anti-VEGF Ophthalmic Drug Producing Area Distribution and Sales Area
Table 24. Players Anti-VEGF Ophthalmic Drug Products Offered
Table 25. Anti-VEGF Ophthalmic Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Anti-VEGF Ophthalmic Drug Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global Anti-VEGF Ophthalmic Drug Sales Market Share Geographic Region (2019-2024)
Table 30. Global Anti-VEGF Ophthalmic Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Anti-VEGF Ophthalmic Drug Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2019-2024)
Table 34. Global Anti-VEGF Ophthalmic Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 37. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2019-2024)
Table 38. Americas Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024) & ($ millions)
Table 39. Americas Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 40. Americas Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 41. APAC Anti-VEGF Ophthalmic Drug Sales by Region (2019-2024) & (K Units)
Table 42. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Region (2019-2024)
Table 43. APAC Anti-VEGF Ophthalmic Drug Revenue by Region (2019-2024) & ($ millions)
Table 44. APAC Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 45. APAC Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 46. Europe Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 47. Europe Anti-VEGF Ophthalmic Drug Revenue by Country (2019-2024) & ($ millions)
Table 48. Europe Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 50. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Country (2019-2024) & (K Units)
Table 51. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Table 52. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Type (2019-2024) & (K Units)
Table 53. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales by Application (2019-2024) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Anti-VEGF Ophthalmic Drug
Table 55. Key Market Challenges & Risks of Anti-VEGF Ophthalmic Drug
Table 56. Key Industry Trends of Anti-VEGF Ophthalmic Drug
Table 57. Anti-VEGF Ophthalmic Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Anti-VEGF Ophthalmic Drug Distributors List
Table 60. Anti-VEGF Ophthalmic Drug Customer List
Table 61. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 62. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 63. Americas Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 64. Americas Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 65. APAC Anti-VEGF Ophthalmic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 66. APAC Anti-VEGF Ophthalmic Drug Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Europe Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Europe Anti-VEGF Ophthalmic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Type (2025-2030) & (K Units)
Table 72. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Type (2025-2030) & ($ millions)
Table 73. Global Anti-VEGF Ophthalmic Drug Sales Forecast by Application (2025-2030) & (K Units)
Table 74. Global Anti-VEGF Ophthalmic Drug Revenue Forecast by Application (2025-2030) & ($ millions)
Table 75. Eyetech Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Eyetech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 77. Eyetech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Eyetech Main Business
Table 79. Eyetech Latest Developments
Table 80. Pfizer Inc Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Pfizer Inc Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 82. Pfizer Inc Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Pfizer Inc Main Business
Table 84. Pfizer Inc Latest Developments
Table 85. Roche Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Roche Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 87. Roche Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Roche Main Business
Table 89. Roche Latest Developments
Table 90. Novartis Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Novartis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 92. Novartis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Main Business
Table 94. Novartis Latest Developments
Table 95. Regeneron Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Regeneron Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 97. Regeneron Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Regeneron Main Business
Table 99. Regeneron Latest Developments
Table 100. Bayer Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Bayer Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 102. Bayer Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Bayer Main Business
Table 104. Bayer Latest Developments
Table 105. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 107. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Regeneron Pharmaceuticals Main Business
Table 109. Regeneron Pharmaceuticals Latest Developments
Table 110. Genentech Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Genentech Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 112. Genentech Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Genentech Main Business
Table 114. Genentech Latest Developments
Table 115. Samsung Bioepis Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Samsung Bioepis Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 117. Samsung Bioepis Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Samsung Bioepis Main Business
Table 119. Samsung Bioepis Latest Developments
Table 120. Biogen Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Biogen Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 122. Biogen Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Biogen Main Business
Table 124. Biogen Latest Developments
Table 125. Qilu Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 127. Qilu Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Qilu Pharmaceutical Main Business
Table 129. Qilu Pharmaceutical Latest Developments
Table 130. Innovent Biologics Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Innovent Biologics Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 132. Innovent Biologics Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Innovent Biologics Main Business
Table 134. Innovent Biologics Latest Developments
Table 135. Kanghong Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 137. Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Kanghong Pharmaceutical Main Business
Table 139. Kanghong Pharmaceutical Latest Developments
Table 140. Taikang Biology Basic Information, Anti-VEGF Ophthalmic Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Taikang Biology Anti-VEGF Ophthalmic Drug Product Portfolios and Specifications
Table 142. Taikang Biology Anti-VEGF Ophthalmic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Taikang Biology Main Business
Table 144. Taikang Biology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-VEGF Ophthalmic Drug
Figure 2. Anti-VEGF Ophthalmic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Ophthalmic Drug Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Ophthalmic Drug Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Ophthalmic Drug Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Pegaptanib
Figure 12. Product Picture of Ranibizumab
Figure 13. Product Picture of Aflibercept
Figure 14. Product Picture of Brolucizumab
Figure 15. Product Picture of Faricimab
Figure 16. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type in 2023
Figure 17. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2019-2024)
Figure 18. Anti-VEGF Ophthalmic Drug Consumed in Online Sales
Figure 19. Global Anti-VEGF Ophthalmic Drug Market: Online Sales (2019-2024) & (K Units)
Figure 20. Anti-VEGF Ophthalmic Drug Consumed in Hospital
Figure 21. Global Anti-VEGF Ophthalmic Drug Market: Hospital (2019-2024) & (K Units)
Figure 22. Anti-VEGF Ophthalmic Drug Consumed in Clinic
Figure 23. Global Anti-VEGF Ophthalmic Drug Market: Clinic (2019-2024) & (K Units)
Figure 24. Anti-VEGF Ophthalmic Drug Consumed in Retail Pharmacy
Figure 25. Global Anti-VEGF Ophthalmic Drug Market: Retail Pharmacy (2019-2024) & (K Units)
Figure 26. Anti-VEGF Ophthalmic Drug Consumed in Others
Figure 27. Global Anti-VEGF Ophthalmic Drug Market: Others (2019-2024) & (K Units)
Figure 28. Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2023)
Figure 29. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application in 2023
Figure 30. Anti-VEGF Ophthalmic Drug Sales by Company in 2023 (K Units)
Figure 31. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company in 2023
Figure 32. Anti-VEGF Ophthalmic Drug Revenue by Company in 2023 ($ millions)
Figure 33. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company in 2023
Figure 34. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Geographic Region (2019-2024)
Figure 35. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Geographic Region in 2023
Figure 36. Americas Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 37. Americas Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 38. APAC Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 39. APAC Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 40. Europe Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 41. Europe Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 42. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 43. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 44. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Country in 2023
Figure 45. Americas Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Figure 46. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 47. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 48. United States Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 49. Canada Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 50. Mexico Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 51. Brazil Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 52. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Region in 2023
Figure 53. APAC Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2019-2024)
Figure 54. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 55. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 56. China Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 57. Japan Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 58. South Korea Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 59. Southeast Asia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 60. India Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 61. Australia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 62. China Taiwan Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 63. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Country in 2023
Figure 64. Europe Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Figure 65. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 66. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 67. Germany Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 68. France Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 69. UK Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 70. Italy Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 71. Russia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 72. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2019-2024)
Figure 73. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 75. Egypt Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 76. South Africa Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 77. Israel Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 78. Turkey Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 79. GCC Countries Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drug in 2023
Figure 81. Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drug
Figure 82. Industry Chain Structure of Anti-VEGF Ophthalmic Drug
Figure 83. Channels of Distribution
Figure 84. Global Anti-VEGF Ophthalmic Drug Sales Market Forecast by Region (2025-2030)
Figure 85. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Anti-VEGF Ophthalmic Drug Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Anti-VEGF Ophthalmic Drug Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Anti-VEGF Ophthalmic Drug
Figure 2. Anti-VEGF Ophthalmic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Ophthalmic Drug Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Ophthalmic Drug Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Ophthalmic Drug Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Ophthalmic Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Pegaptanib
Figure 12. Product Picture of Ranibizumab
Figure 13. Product Picture of Aflibercept
Figure 14. Product Picture of Brolucizumab
Figure 15. Product Picture of Faricimab
Figure 16. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Type in 2023
Figure 17. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Type (2019-2024)
Figure 18. Anti-VEGF Ophthalmic Drug Consumed in Online Sales
Figure 19. Global Anti-VEGF Ophthalmic Drug Market: Online Sales (2019-2024) & (K Units)
Figure 20. Anti-VEGF Ophthalmic Drug Consumed in Hospital
Figure 21. Global Anti-VEGF Ophthalmic Drug Market: Hospital (2019-2024) & (K Units)
Figure 22. Anti-VEGF Ophthalmic Drug Consumed in Clinic
Figure 23. Global Anti-VEGF Ophthalmic Drug Market: Clinic (2019-2024) & (K Units)
Figure 24. Anti-VEGF Ophthalmic Drug Consumed in Retail Pharmacy
Figure 25. Global Anti-VEGF Ophthalmic Drug Market: Retail Pharmacy (2019-2024) & (K Units)
Figure 26. Anti-VEGF Ophthalmic Drug Consumed in Others
Figure 27. Global Anti-VEGF Ophthalmic Drug Market: Others (2019-2024) & (K Units)
Figure 28. Global Anti-VEGF Ophthalmic Drug Sale Market Share by Application (2023)
Figure 29. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Application in 2023
Figure 30. Anti-VEGF Ophthalmic Drug Sales by Company in 2023 (K Units)
Figure 31. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Company in 2023
Figure 32. Anti-VEGF Ophthalmic Drug Revenue by Company in 2023 ($ millions)
Figure 33. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Company in 2023
Figure 34. Global Anti-VEGF Ophthalmic Drug Sales Market Share by Geographic Region (2019-2024)
Figure 35. Global Anti-VEGF Ophthalmic Drug Revenue Market Share by Geographic Region in 2023
Figure 36. Americas Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 37. Americas Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 38. APAC Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 39. APAC Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 40. Europe Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 41. Europe Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 42. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales 2019-2024 (K Units)
Figure 43. Middle East & Africa Anti-VEGF Ophthalmic Drug Revenue 2019-2024 ($ millions)
Figure 44. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Country in 2023
Figure 45. Americas Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Figure 46. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 47. Americas Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 48. United States Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 49. Canada Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 50. Mexico Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 51. Brazil Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 52. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Region in 2023
Figure 53. APAC Anti-VEGF Ophthalmic Drug Revenue Market Share by Region (2019-2024)
Figure 54. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 55. APAC Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 56. China Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 57. Japan Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 58. South Korea Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 59. Southeast Asia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 60. India Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 61. Australia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 62. China Taiwan Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 63. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Country in 2023
Figure 64. Europe Anti-VEGF Ophthalmic Drug Revenue Market Share by Country (2019-2024)
Figure 65. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 66. Europe Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 67. Germany Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 68. France Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 69. UK Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 70. Italy Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 71. Russia Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 72. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Country (2019-2024)
Figure 73. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Anti-VEGF Ophthalmic Drug Sales Market Share by Application (2019-2024)
Figure 75. Egypt Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 76. South Africa Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 77. Israel Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 78. Turkey Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 79. GCC Countries Anti-VEGF Ophthalmic Drug Revenue Growth 2019-2024 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drug in 2023
Figure 81. Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drug
Figure 82. Industry Chain Structure of Anti-VEGF Ophthalmic Drug
Figure 83. Channels of Distribution
Figure 84. Global Anti-VEGF Ophthalmic Drug Sales Market Forecast by Region (2025-2030)
Figure 85. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Anti-VEGF Ophthalmic Drug Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Anti-VEGF Ophthalmic Drug Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Anti-VEGF Ophthalmic Drug Revenue Market Share Forecast by Application (2025-2030)
